All In Biotech

Drug Trial Radar · NCT07308574

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

Multicenter, Open-label, Single-arm, Post-Marketing Clinical Study to Evaluate the Efficacy and Safety of Ravulizumab in Participants Clinically Diagnosed as Atypical Hemolytic Uremic Syndrome

Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Dec 19, 2025

Primary completion

Jun 25, 2027

Study completion Jun 25, 2027

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).

Conditions

  • aHUS
  • Atypical Hemolytic Uremic Syndrome

Interventions

  • RavulizumabDrug

    Participants will receive ravulizumab via IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Showing Improvement in Platelet Count During the 26-week Ravulizumab TreatmentTime frame: Baseline up to Week 26

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Bunkyō City, Japan · Not yet recruiting

  • Research Site

    Hirakata-shi, Japan · Not yet recruiting

  • Research Site

    Iruma-Gun, Japan · Recruiting

  • Research Site

    Kyoto, Japan · Not yet recruiting

  • Research Site

    Matsumoto-shi, Japan · Not yet recruiting

  • Research Site

    Miyazaki, Japan · Not yet recruiting

  • Research Site

    Nagoya, Japan · Recruiting

  • Research Site

    Nara, Japan · Not yet recruiting

  • Research Site

    Nerima-ku, Japan · Not yet recruiting

  • Research Site

    Sapporo, Japan · Not yet recruiting

  • Research Site

    Shinjuku-ku, Japan · Not yet recruiting

  • Research Site

    Tsu, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.